Polyrizon (Nasdaq: PLRZ) expands U.S. patent claims for intranasal drug delivery platform

Rhea-AI Filing Summary

Polyrizon Ltd. filed a Form 6-K to share that it has submitted amended claims in its U.S. patent application covering its proprietary intranasal drug delivery platform. The new claims extend protection from the core mucoadhesive composition to related drug delivery systems and methods of use.

The expanded claim set focuses on compositions with sulfated polysaccharide polymers and additional polymers that form a continuous film on epithelial mucosa, aiming to improve delivery of active pharmaceutical ingredients. This step supports Polyrizon’s strategy to strengthen its global intellectual property around its intranasal hydrogel technologies, including its Capture and Contain and Trap and Target platforms.

Key Terms

intranasal drug delivery platform, mucoadhesive composition, sulfated polysaccharide polymers, epithelial mucosa, +2 more

6 terms

intranasal drug delivery platform technical

"U.S. patent application for its proprietary intranasal drug delivery platform."

mucoadhesive composition technical

"to include not only the core mucoadhesive composition, but also drug delivery systems"

sulfated polysaccharide polymers technical

"compositions comprising sulfated polysaccharide polymers and additional polymeric components"

Long chains of sugar molecules that have been chemically tagged with sulfate groups, like beads on a string with tiny sticky flags attached. These tags change how the polymer interacts with water and biological systems, giving properties such as increased thickness, anti-clotting or antiviral activity, and altered absorption. Investors care because these materials are used in drugs, medical products and specialty formulations, so their performance, manufacturing complexity, regulatory status and patentability can affect commercial value and risk.

epithelial mucosa medical

"form a uniform and continuous film upon contact with epithelial mucosa"

A layer of cells that lines internal surfaces and cavities of the body and often produces mucus, serving as a protective and selective barrier (for example in the nose, lungs, digestive tract or mouth). For investors, it matters because this tissue is a common target or route for drugs, vaccines and medical devices; its condition affects how treatments are absorbed, how safe they are, and whether regulators will approve a product — think of it as the wallpaper and weatherproofing of an internal room that determines how well interventions work.

Capture and Contain TM (C&C) hydrogel technology technical

"Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology"

forward-looking statements regulatory

"This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of May 2026

Commission file number: 001-42375

Polyrizon Ltd.

(Translation of registrant’s name into English)

8 Ha-Pnina Street

Raanana, 4321545, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on May 4, 2026, titled “Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform.”

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform”

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Polyrizon Ltd.
Date: May 4, 2026	By:	/s/ Tomer Izraeli
	Name:	Tomer Izraeli
	Title:	Chief Executive Officer

2

Exhibit 99.1

Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform

Raanana, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the submission of amended claims in its U.S. patent application for its proprietary intranasal drug delivery platform.

The amended claims expand the scope of protection of the Company’s technology to include not only the core mucoadhesive composition, but also drug delivery systems and methods of use, which are designed to enhance the effectiveness of medications by increasing their residence time and ensuring close contact with mucosal tissues. This development aligns with the Company’s strategy to strengthen its global intellectual property portfolio.

The expanded claims relate to compositions comprising sulfated polysaccharide polymers and additional polymeric components that form a uniform and continuous film upon contact with epithelial mucosa, enabling improved delivery of active pharmaceutical ingredients (APIs).

Key Potential Features of the Platform:

● Prolonged Residence Time: Enhancing the duration that drugs remain at the site of administration, supporting improved absorption and efficacy.

● Improved Bioavailability: Increasing the effectiveness of APIs through enhanced mucosal interaction and retention.

● Controlled Film Formation: Transformation into a uniform, continuous film upon contact with mucosal surfaces.

● Versatility: Compatibility with a wide range of drug types and therapeutic indications.

Tomer Izraeli, CEO of Polyrizon, commented, “The submission of amended claims in our U.S. patent application represents another important step in strengthening our intellectual property protection. We believe that expanding the scope of protection to include drug delivery systems and methods of use enhances the value and potential applicability of our platform across a broad range of therapeutic areas.”

The Company’s platform leverages the unique properties of intranasal delivery to facilitate both local and systemic administration of drugs. By enhancing retention and interaction with mucosal tissues, the technology has the potential to improve treatment outcomes across multiple indications.

About Polyrizon

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain ^TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target, or T&T. For more information, please visit https://polyrizon-biotech.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its strategy to strengthen its global intellectual property portfolio and its belief that expanding the scope of its intellectual property protection to include drug delivery systems and methods of use enhances the value and potential applicability of its platform across a broad range of therapeutic areas. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company.  Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.

Contacts:

Michal Efraty
Investor Relations
IR@polyrizon-biotech.com

FAQ

What did Polyrizon (PLRZ) announce in its latest Form 6-K?

Polyrizon announced it submitted amended claims in its U.S. patent application for its intranasal drug delivery platform. The changes broaden patent coverage from the core mucoadhesive composition to include drug delivery systems and methods of use, reinforcing the company’s intellectual property position around intranasal hydrogels.

How do Polyrizon’s amended U.S. patent claims expand protection?

The amended claims extend protection beyond the basic mucoadhesive composition to cover related drug delivery systems and methods of use. They focus on compositions with sulfated polysaccharide polymers and other components that form a continuous film on mucosal surfaces, supporting improved delivery of active pharmaceutical ingredients through the nose.

What technology is covered by Polyrizon’s intranasal drug delivery platform?

Polyrizon’s platform centers on innovative intranasal hydrogels that form a uniform film on epithelial mucosa. These compositions, built from sulfated polysaccharide polymers and additional polymers, aim to increase residence time in the nasal cavity and keep close contact with mucosal tissues, potentially enhancing drug effectiveness.

How does Polyrizon’s Capture and Contain (C&C) technology work?

Capture and Contain is a hydrogel-based technology delivered as a nasal spray that forms a thin shield-like barrier in the nasal cavity. It is designed as a “biological mask” to help prevent viruses and allergens from contacting nasal epithelial tissue while the company also explores enhanced bioadhesion and prolonged retention for drug delivery.

What is Polyrizon’s Trap and Target (T&T) technology?

Trap and Target is Polyrizon’s additional intranasal technology focused on delivering active pharmaceutical ingredients. It is in an earlier, pre-clinical development stage and aims to use the company’s hydrogel concepts to enable targeted nasal administration of drugs, complementing the barrier-focused Capture and Contain platform.

Why is intellectual property important for Polyrizon’s intranasal platform?

Intellectual property is central because Polyrizon is a development-stage biotech relying on proprietary intranasal hydrogel technologies. Strengthening U.S. patent claims around compositions, delivery systems, and methods of use helps protect potential future products and supports the company’s broader global intellectual property portfolio strategy.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE TITLED: "POLYRIZON ANNOUNCES U.S. PATENT EXPANSION FOR ITS INTRANA 12.7 KB